Phaseline

Companies › Supernus Pharmaceuticals

Supernus Pharmaceuticals: clinical trials, targets and expected readouts

4 active drug programs in 6 registered trials: 3 Phase 2, 1 Phase 4, 1 Phase 3, 1 Phase 1; Psychiatry, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Viloxazine Hydrochloride (SPN-812)
Norepinephrine transporter inhibitor
SLC6A2Phase 4Attention-Deficit/Hyperactivity DisorderJan 2028
SPN-821
selective, direct enhancer of mTORC1 cellular signaling
MTORPhase 2Major Depressive Disorder (MDD)Dec 2026
Huperzine A (SPN-817)
Acetylcholinesterase inhibitor
ACHEPhase 2Focal Onset Seizures; EpilepsyAug 2027
BIS-001-ER
acetylcholinesterase inhibitor
ACHEPhase 1Focal Impaired Awareness SeizuresDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02736656Viloxazine Hydrochloride (SPN-812)Phase 3Attention-Deficit/Hyperactivity DisorderPsychiatrySep 2026
NCT03474770BIS-001-ERPhase 1Focal Impaired Awareness SeizuresNeurologyDec 2026
NCT07226661SPN-821Phase 2Major Depressive Disorder (MDD)PsychiatryDec 2026
NCT06798896Huperzine A (SPN-817)Phase 2Focal Onset SeizuresNeurologyAug 2027
NCT05518578Huperzine A (SPN-817)Phase 2EpilepsyNeurologyDec 2027
NCT04781140Viloxazine Hydrochloride (SPN-812)Phase 4Attention-Deficit/Hyperactivity DisorderPsychiatryJan 2028

From the company's SEC filings

Cash of $176m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ACHE (2) SLC6A2 (1) MTOR (1)

Companies with the same targets

Axsome Therapeutics Wanbangde Pharmaceutical Group Inventage Lab. Alpha Cognition Currax Pharmaceuticals Otsuka Resilient Pharmaceuticals Theravance Biopharma Remedy Definium Therapeutics US

Companies built like this

Alkermes Neurocrine Biosciences Noema Pharma Reunion Neuroscience TrueBinding

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.